3rd IMPACCT Real World Evidence Summit Europe

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI transforms big data analysis, it has never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, and influence decision-making across regulators, payers, providers, and patients.
 
The 3rd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE, Evidence Generation, and Medical Affairs to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
 
With a tight focus on leveraging AI for big data analysis, accessing standardised and high-quality datasets, and creating a robust integrated evidence strategy, join 60+ industry pioneers from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice.